PLANTATION, Fla., Sept. 12, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced a key appointment that is designed to position the company for the future. SooYoung Lee, PhD has returned to Goodwin Biotechnology as Chief Operating Officer. He will report to newly appointed CEO, Karl Pinto, and will oversee all aspects of Goodwin's Contract Manufacturing Operations.
SooYoung has had a distinguished career in the biological industry spanning several decades. After earning his PhD in Biochemical Engineering at Cornell University, he held several leadership positions at leading biopharmaceutical companies and CMO's such as SAIC Frederick, Schering-Plough Research Institute, Wyeth Lederle Vaccines, AppTec, Neose Technologies and Genencor. He also has extensive experience in international biotechnology operations, having established and served as the Director of the Biopharmaceutical Manufacturing Technology Center (BMTC) in Singapore, and as a Senior Member, he helped establish the International Vaccine Institute (IVI) in Seoul, Korea.
"I am excited about the opportunity to team up with the dedicated staff at Goodwin Biotechnology," said SooYoung Lee, PhD. "Since its inception in 1992, the company has a distinguished history and a great track record of providing quality Contract Development and Manufacturing services and GMP clinical material as the first comprehensive CMO focusing on cell culture-based biologics. Our goal is to continue working with our clients as a development and manufacturing partner to manufacture cGMP compliant clinical trial material in a timely and cost-effective manner. Being uniquely flexible in our client engagements and shortening the time from bench to clinic will have a critical impact on the success of our partners and ultimately benefit patients and their families."
"SooYoung's experiences in process development, tech transfer and GMP manufacturing along with strategic planning and execution will help ensure the delivery of the highest quality services and products that are in compliance with current Good Manufacturing Practices (cGMP) to our clients, ranging from the smallest biotech start-ups to large biopharma companies," noted Karl Pinto. "With this significant addition, we are poised to take the company to new heights."
About Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines and Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a road map to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at www.GoodwinBio.com.
For more information on the process development and GMP manufacturing of biologics, please contact Goodwin Biotechnology:
Business Development Manager
SOURCE Goodwin Biotechnology, Inc.